A Prospective Clinical Trial Evaluating the Safety and Efficacy of Radiotherapy Combined with Immunotherapy in Advanced Refractory Solid Malignancies After Standard Treatment Failure/drug Resistance.

The goal of this clinical trial is to find a new radioimmunotherapy regimen for advanced malignancies with multiple metastatic after standard treatment failure/drug resistance. The main questions it aims to answer is: the safety and efficacy of the new regimen for advanced multiple metastatic solid tumors standard treatment failure/drug resistance, and explore the impact on immune function. Participants will receive the combination of radiotherapy and immunotherapy.

开始日期2025-08-01

申办/合作机构

中日友好医院

NCT06459427

/ Not yet recruitingN/AIIT

Research on Minimally Invasive Surgical Strategies for Brainstem Hemorrhage Assisted by Robotics

The purpose of this clinical trial is to observe the improvements in clinical symptoms and imaging outcomes for brainstem hemorrhage using robot-assisted stereotactic puncture, evaluate the clinical efficacy and safety of this treatment, and explore the development of a high-precision, intelligent, and individualized microsurgical diagnosis and treatment process for brainstem hemorrhage. The main questions it aims to address are:
Establish a multi-center clinical database for brainstem hemorrhage.
Clinically observe and evaluate the intervention effects of robot-assisted stereotactic puncture on brainstem hemorrhage, compare it with the traditional conservative treatment control group, and investigate its efficacy and impact on patient survival, motor evoked potentials, and the degree of neurological deficits.
Optimize the Artificial Intelligence (AI) algorithm-based robotic surgical assistance system, and explore the prediction of preoperative brainstem hematoma stability and hematoma path planning.
Participants in the experimental group will:
Undergo robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture
Receive conservative non-surgical treatment.
If there is a control group: the researchers will compare the conservative non-surgical treatment group to evaluate the effectiveness of robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture.

开始日期2025-07-01

申办/合作机构

中日友好医院

NCT06945510

/ Not yet recruitingN/AIIT

A Multi-center Study to Evaluate the Economic and Clinical Impact of PCT Guided Antibiotics Use in Critically Ill Adult Patients in China.

Procalcitonin (PCT) has been widely used in the diagnosis and treatment of bacterial infectious diseases in China. The investigators aim to establish an algorithm based on BRAHMS PCT (VIDAS PCT) for patients with severe infections or sepsis in the EICU to reduce antibiotic exposure and verify its validity in the reduction of antibiotic exposure, clinical outcomes and costs saving.

开始日期2025-06-30

申办/合作机构

中日友好医院

100 项与中日友好医院相关的临床结果

登录后查看更多信息

0 项与中日友好医院相关的专利（医药）

登录后查看更多信息

10,758

项与中日友好医院相关的文献（医药）

2025-12-31·International Journal of Hyperthermia

Clinical study on the relationship between the incidence of complications and tumour size after thermal ablation of benign thyroid nodules

Article

作者: Wu, Jie ; Peng, Li-li ; Wei, Ying ; Cao, Shi-liang ; Li, Yan ; Yu, Ming-an ; Zhao, Han-xiao ; Yu, Na ; Zhao, Zhen-long

OBJECTIVEThe present study aimed to analyze the relationship between the incidence of complications and tumor size following thermal ablation of benign thyroid nodules (BTNs).METHODSIn this retrospective study, 1198 patients who underwent thermal ablation for unifocal BTN were enrolled. Receiver Operating Characteristic analysis was performed to select the cutoff values of the maximum diameter (MD) for dividing patients into different groups or subgroups. Multivariable logistic regression was performed to identify the risk factors. Propensity score matching (PSM) was employed to control for confounding variables.RESULTSThe overall complication rate was 3.8% (45/1198). Major complications included hoarseness (2.4%), nodule rupture (0.3%) and delayed hemorrhage (0.1%), whereas minor complications were limited to intraoperative hemorrhage (0.9%). The difference in the overall complication rate between the smaller group (< 3.15 cm) and the larger group (> 3.15 cm) was significant (1.0% vs. 6.5%, p < 0.001). In the subgroup analysis, a significant difference was observed between the 3.15-4.15 cm and > 4.15 cm subgroups (4.2% vs. 8.7%, p = 0.023); however, no significant difference was identified between the < 2.35 and 2.35-3.15 cm subgroups (0.6% vs. 1.6%, p = 0.390). Multivariable logistic regression indicated that MD and the nodule component were associated with complications. After PSM, no significant difference in complication rates was observed between MWA and RFA in either the smaller group (p = 1.000) or the larger group (p = 0.186).CONCLUSIONSThe incidence of complications in thermal ablation is greater for larger thyroid nodules, particularly for predominantly solid nodules with MDs greater than 3.15 cm.

2025-12-31·International Journal of Hyperthermia

Thyroid nodule rupture after thermal ablation for benign thyroid nodules: incidence, risk factors, and clinical management

Article

作者: Peng, Li-Li ; Li, Yan ; Wei, Ying ; Yu, Na ; Wu, Jie ; Cao, Shi-Liang ; Liu, Yu-tong ; Yu, Ming-an ; Zhao, Zhen-Long

BACKGROUNDThyroid nodule rupture (TNR) is a rare and severe complication after thermal ablation (TA), mostly from benign thyroid nodules (BTN).OBJECTIVETo summarize the incidence of TNR after TA and analyze the causes and prevention strategies.MATERIALS AND METHODSThis retrospective study enrolled 3971 patients who underwent TA for BTN from January 2014 to March 2024. The incidence, causes, and risk factors of TNR were analyzed. Propensity score matching (PSM) controlled for confounding factors. Multivariate regression identified risk factors for TNR. ROC curves determined the optimal cutoff value for the maximum diameter (MD) for TNR.RESULTSTNR occurred in 8 cases [0.2% (8/3971)]. The mean time from TA to TNR was 29.6 ± 13.0 days (range, 20-60 days). After PSM, MD was larger in the TNR group than in the non-TNR group [mean 4.1 ± 1.6 cm vs. mean 1.8 ± 1.2 cm; p < 0.001]. The optimal cutoff value of MD for TNR was 2.75 cm. After PSM, the incidence of pressure on the ablation zone was significantly higher in the TNR group than in the non-TNR group [100% (8/8) vs. 0 (0/32); p < 0.001], which has been suspected as a case of TNR. Antibiotic drugs, aspiration, or incision drainage could successfully manage all TNR cases.CONCLUSIONTNR could be encountered in case of pressure on the BTN after TA. Protecting the ablation site from pressure might be crucial in preventing TNR, especially within two months. TNR is more likely to occur if the MD of BTN exceeds 2.75 cm under pressure. Observation, antibiotics, and aspiration could successfully manage all TNR cases.

2025-12-31·International Journal of Hyperthermia

Comparison of US-guided thermal ablation and surgery for papillary thyroid cancer: a systematic review and meta-analysis

Review

作者: Cao, Shi-liang ; Wei, Ying ; Zhao, Zhen-long ; Wu, Jie ; Yu, Na ; Yu, Ming-an

OBJECTIVEWe conducted the systematic review and meta-analysis to comprehensively compare ablation and surgery in terms of effectiveness, safety and multiple factors affecting life quality of patients with papillary thyroid cancer (PTC).METHODSPubMed, Embase, Scopus, Web of Science and EBSCO were searched for relevant studies published between January 1980 and September 2023. Two reviewers independently extracted data according to the PRISMA recommendations and assessed the quality of each study with the Cochrane Risk of Bias Tool. Pooled analyses were performed using random or fixed-effects models, as appropriate.RESULTSA total of 4829 patients with PTC from 19 eligible studies were included. Through the meta-analysis, similar tumor progression (OR: 1.07; 95% CI 0.78, 1.48; p = 0.66) and recurrence-free survival (OR: 0.86; 95% CI, 0.55, 1.34; p = 0.50) were found between the patients undergoing ablation and those undergoing surgery. More strikingly, the lower risk of major complications (OR: 0.31; 95% CI 0.24, 0.41; p < 0.001), the shorter hospital stay (MD = 3.67 d; 95% CI, -4.89, -2.44; p < 0.001), the abbreviated procedure time (MD: -66.33 min, 95% CI, -77.08, -55.59; p < 0.001), the less intraoperative blood loss (MD: -27.43 ml, 95% CI, -34.60, -20.27; p < 0.001) and the lower treatment cost (MD: -860.42 USD, 95% CI, -1008.03, -712.81; p < 0.001) were noticed in ablation techniques compared to surgical operation. Thermal ablation has shown multiple advantages by virtue of its percutaneous puncture compared with surgical resection.CONCLUSIONAs an effective, safe, minimally invasive and economical modality, thermal ablation might be a promising alternative to existing PTC management options.

224

项与中日友好医院相关的新闻（医药）

2025-05-05

·ioncology

IGCC前瞻丨中国专家20项口头报告摘要闪耀国际舞台

IGCC 2025微专辑扫描二维码可查看更多内容编者按由国际胃癌学会（IGCA）主办的第16届国际胃癌大会（IGCC 2025）将于2025年5月7~10日在荷兰阿姆斯特丹隆重召开。作为全球胃癌研究领域具影响力的学术盛会，本届大会将汇聚来自世界各地的顶尖专家学者，聚焦胃癌诊疗前沿进展。值得关注的是，中国专家将在多个专题会场发表重要研究成果，展现我国在该领域的学术影响力。经《肿瘤瞭望消化时讯》系统梳理会议日程，现共整理出20项中国专家入选的口头报告摘要标题（中英文对照）供读者预览。若有遗漏或表述偏差，诚挚欢迎学界同仁批评指正。一、5月8日专题报告Session 1a：分期专场时间：11:45中文标题：多参数MRI与双能CT在胃癌局部区域分期中的对比研究英文标题：Multiparametric MRI versus Dual-Energy CT in Gastric Cancer Locoregional Staging专家：Qiong Li，南京医科大学第一附属医院时间：12:05中文标题：基于优化淋巴结分期的胃癌新辅助治疗后ypTNM分期细化英文标题：Refined ypTNM Staging for Gastric Cancer After Neoadjuvant Therapy Based on Optimal Lymph Node Staging专家：Baolong Li，福建医科大学附属协和医院Session 1b：肿瘤内科-免疫治疗专场时间：11:45中文标题：术前免疫治疗与dMMR/MSI-H胃癌病理反应改善相关英文标题：Preoperative immunotherapy is associated with better pathological response in dMMR/MSI-H gastric cancer专家：Hong Zeng，复旦大学附属中山医院时间：12:05中文标题：蛋白质组学分析预测胃癌新辅助放化疗免疫疗效英文标题：Proteomic Analysis Predicts Therapeutic Outcomes of Neoadjuvant Chemo-immunotherapy in Gastric Cancer Patients专家：崔昊，中国人民解放军总医院第一医学中心Session 1c：胃肠病学/内镜/早期胃癌专场时间：11:55中文标题：全腹腔镜与腹腔镜辅助远端胃癌根治术对早期胃癌患者生活质量的影响分析英文标题：Morbidity and quality of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer’s life专家：黄华，复旦大学附属肿瘤医院Session 2a：肿瘤内科-靶向治疗专场时间：16:40中文标题：T细胞激活增强抗HER2介导的胃癌抗体依赖性细胞毒性英文标题：T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer专家：薛子睿，复旦大学附属中山医院Session 2b：放射肿瘤学专场时间：16:30中文标题：可切除食管胃结合部腺癌新辅助斯鲁利单抗联合放化疗的Ⅱ期更新结果英文标题：Neoadjuvant Serplulimab with Concurrent Chemoradiotherapy in Resectable Esophagogastric Junction Adenocarcinoma: Phase 2 Updated Results专家：赵林，北京协和医院时间：16:40中文标题：可切除食管胃腺癌放化疗价值的Meta分析英文标题：The value of chemoradiation therapy for resectable esopho-gastric adenocarcinomas: A meta-analysis of randomized clinical trials专家：Tao Fu，中日友好医院Session 2c：胃癌手术创新专场时间：16:40中文标题：D2+CME根治术对局部进展期胃癌的肿瘤学疗效：RCT三年随访结果英文标题：The oncological efficacy of D2+CME for locally advanced gastric cancer: 3-year outcomes of a RCT专家：龚建平，华中科技大学同济医学院附属同济医院二、5月9日专题报告3x接受口头摘要全体会议：HDGC/预康复专场时间：9:40中文标题：多学科预康复改善老年虚弱胃癌患者临床结局英文标题：Supervised multimodal prehabilitation to improve the clinical outcomes of frail elderly patients with gastric cancer专家：Yuqi Sun，青岛大学附属医院Session 3a：病理学/转化研究专场时间：11:55中文标题：FGFBP2+NK细胞作为胃癌免疫治疗预测性生物标志物的角色解析英文标题：Unraveling the Role of FGFBP2+NK Cells as Predictive Biomarkers in Gastric Adenocarcinoma Immunotherapy专家：潘宏达，复旦大学附属肿瘤医院Session 3b：人工智能与精准手术专场时间：11:45中文标题：机器学习模型预测胃癌患者术后并发症英文标题：Machine Learning Models for Predicting Postoperative Surgical Complications in Gastric Cancer Patients专家：Xiaohan Cui，山东大学齐鲁医院时间：12:05中文标题：基于多场景血管识别的AI驱动胃癌微创手术导航系统英文标题：AI-driven Surgical Navigation System based on Multi-scene Vessel Recognition for Minimally Invasive Gastric Cancer Surgery专家：Hao Chen，南方医科大学南方医院Session 3c：生活质量/支持治疗专场时间：11:55中文标题：中国胃癌手术质量与经济学评价：基于PACAGE研究分析英文标题：Surgical Quality and Economic Evaluation of Gastric Cancer Surgery in China: Analysis of PACAGE study专家：吴舟桥，北京大学肿瘤医院Session 4b：多模态治疗专场时间：16:30中文标题：AS与CAPOX在Ⅲ期胃腺癌术后化疗中的生存与安全性更新英文标题：AS versus CAPOX in postoperative chemotherapy for stage Ⅲ gastric adenocarcinoma patients: survival and safety update专家：俞鹏飞，浙江省肿瘤医院Session 4c：手术拓展-局限性Ⅳ期胃癌治疗专场时间：16:40中文标题：腹腔联合静脉化疗对比静脉紫杉醇+S-1治疗腹膜转移胃癌：DRAGON-01试验结果英文标题：Intraperitoneal+intravenous vs. intravenous paclitaxel+S-1 in gastric cancer with peritoneal metastasis: Results from DRAGON-01 trial专家：严超，上海交通大学医学院附属瑞金医院三、5月10日专题报告3x接受口头摘要全体会会议：手术专场时间：9:30中文标题：食管胃结合部腺癌纵隔淋巴结清扫的多中心队列研究中期分析英文标题：Lower mediastinal lymphadenectomy for adenocarcinoma of esophagogastric junction: interim analysis of a multicenter cohort study专家：李子禹，北京大学肿瘤医院时间：9:40中文标题：全腹腔镜与腹腔镜辅助全胃切除术疗效比较：CLASS08多中心RCT研究英文标题：The Efficacy of Totally Laparoscopic versus Laparoscopic-Assisted Total Gastrectomy: The CLASS08 Multicentre Randomized Controlled Trial专家：Qingya Li，南京医科大学第一附属医院Session 5a：肿瘤内科-新药与技术专场时间：11:55中文标题：替雷利珠单抗联合安罗替尼与XELOX一线治疗晚期胃/胃食管结合部腺癌（TALENT研究）英文标题：Tislelizumab Combined with Anlotinib and XELOX as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (TALENT)专家：Ling Ma，南京医科大学第一附属医院Session 5c：视频专场：如何应对治疗失败时间：11:45中文标题：D2+CME手术技术演示英文标题：D2+CME surgery专家：龚建平，华中科技大学同济医学院附属同济医院综上，本届IGCC大会中，中国专家在胃癌的分期诊断、免疫治疗、微创手术、多学科预康复等领域贡献多项突破性研究成果，涵盖临床分期优化、新型靶向药物联合方案、AI手术辅助系统等技术进展。特别关注领域包括：免疫治疗标志物探索（如dMMR/MSI-H分型与FGFBP2+NK细胞）、手术技术创新（如D2+CME根治术、全腹腔镜操作安全性）、多学科综合治疗（新辅助放化疗、多学科预康复模式）等。这些研究不仅展现中国在胃癌诊疗领域的国际影响力，更为全球患者带来潜在诊疗方案优化契机。期待中国专家在阿姆斯特丹的学术舞台上发出更强音！（来源：肿瘤瞭望消化时讯）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床2期免疫疗法

2025-05-01

·医脉通

刚刚！国家卫健委成立调查组，对肖某、董某及有关机构开展调查

坚持实事求是、客观公正原则！来源 | 国家卫健委5月1日，国家卫生健康委新闻发言人表示，近日，我委关注到中日友好医院胸外科肖某被举报所引发的相关舆情。我委已成立调查组，坚持实事求是、客观公正原则，联合有关方面对事件涉及的肖某、董某及有关机构等进行认真调查核查，对发现的违法违规问题将依法依纪严肃处理。责编｜米子封面图来源｜视觉中国国家卫健委明确：未来3年，这两大科室将重点发展 | 医脉政事儿他自行换药20年后，开始出现高热、腹部隆起、身体溃烂……医生见状都震惊了！丨医起推理吧医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。☟戳这里，更有料！

2025-05-01

·丁香园

国家卫生健康委对近日肖某引发舆情问题开展调查

5 月 1 日早上，国家卫健委发布消息。国家卫生健康委新闻发言人表示，近日，我委关注到中日友好医院胸外科肖某被举报所引发的相关舆情。我委已成立调查组，坚持实事求是、客观公正原则，联合有关方面对事件涉及的肖某、董某及有关机构等进行认真调查核查，对发现的违法违规问题将依法依纪严肃处理。信息来源：健康中国公众号丁香园是面向医疗从业者的专业平台，以「助力中国医生」为己任。在丁香园，可以和同行讨论病例，在线学习公开课，使用用药助手等临床决策工具，在丁香人才找可靠医疗岗位。

高管变更

100 项与中日友好医院相关的药物交易

登录后查看更多信息

100 项与中日友好医院相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年05月30日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

CN118252914 ( BPI )	鳞状细胞肿瘤更多	药物发现
CN118370816 ( IL-2 )	炎症更多	药物发现
前列地尔脂质体 ( EP1 )	血管疾病更多	无进展
LC09	手足综合症更多	无进展